CIK 0001393434 · Large accelerated filer
OCULAR THERAPEUTIX, INC
Sign in to watch- Ticker
- OCUL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 781-357-4000
- Business address
- 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
- Former names
- I-THERAPEUTIX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $799,174
- in 9 filings, $788K under 10b5-1 plans
Net −$799,174. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-11 | Nayak Sanjay Chief Strategy Officer | Grant or award | +111,000 | 285,380 | ||
| 2025-02-11 | Nayak Sanjay Chief Strategy Officer | Grant or award · Stock Option (Right to Buy) | +334,000 | 334,000 | ||
| 2025-02-04 | Notman Donald See Remarks | Sale | −11,119 | $7.81 | $87K | 193,444 |
| 2025-01-31 | Notman Donald See Remarks | Sale | −6,301 | $7.84 | $49K | 204,563 |
| 2024-11-25 | Heier Jeffrey S. Chief Scientific Officer | Sale 10b5-1 | −2,948 | $9.01 | $27K | 269,059 |
| 2024-11-25 | Kaiser Peter Chief Development Officer | Sale 10b5-1 | −2,897 | $9.01 | $26K | 213,087 |
| 2024-11-25 | Nayak Sanjay Chief Strategy Officer | Sale 10b5-1 | −1,814 | $9.00 | $16K | 174,380 |
| 2024-11-25 | Dugel Pravin See Remarks | Sale 10b5-1 | −20,680 | $9.01 | $186K | 791,793 |
| 2024-10-07 | Anderman Todd Chief Legal Officer | Grant or award | +98,700 | 98,700 | ||
| 2024-10-07 | Anderman Todd Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +296,500 | 296,500 | ||
| 2024-10-02 | Kaiser Peter Chief Development Officer | Grant or award | +100,000 | 215,984 | ||
| 2024-10-02 | Kaiser Peter Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2024-10-02 | Heier Jeffrey S. Chief Scientific Officer | Grant or award | +100,000 | 272,007 | ||
| 2024-10-02 | Heier Jeffrey S. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2024-08-29 | Notman Donald See Remarks | Grant or award | +11,034 | 208,988 | ||
| 2024-08-29 | Notman Donald See Remarks | Grant or award · Stock Option (Right to Buy) | +33,602 | 33,602 | ||
| 2024-08-23 | Nayak Sanjay Chief Strategy Officer | Sale 10b5-1 | −1,832 | $9.02 | $17K | 176,194 |
| 2024-08-23 | Dugel Pravin See Remarks | Sale 10b5-1 | −20,880 | $9.02 | $188K | 812,473 |
| 2024-07-24 | LINDSTROM RICHARD L MD Director | Grant or award | +12,000 | 162,704 | ||
| 2024-07-24 | LINDSTROM RICHARD L MD Director | Grant or award · Stock Option (Right to Buy) | +36,000 | 36,000 |
Page 7 of 8 · 158 trades